KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) Debt to Equity: 2011-2024

Historic Debt to Equity for Supernus Pharmaceuticals (SUPN) over the last 7 years, with Dec 2024 value amounting to $0.05.

  • Supernus Pharmaceuticals' Debt to Equity fell 76.86% to $0.01 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.13, marking a year-over-year decrease of 34.28%. This contributed to the annual value of $0.05 for FY2024, which is 19.11% down from last year.
  • Supernus Pharmaceuticals' Debt to Equity amounted to $0.05 in FY2024, which was down 19.11% from $0.06 recorded in FY2023.
  • Supernus Pharmaceuticals' 5-year Debt to Equity high stood at $0.52 for FY2021, and its period low was $0.02 during FY2022.
  • Over the past 3 years, Supernus Pharmaceuticals' median Debt to Equity value was $0.05 (recorded in 2024), while the average stood at $0.04.
  • Per our database at Business Quant, Supernus Pharmaceuticals' Debt to Equity skyrocketed by 1,153.04% in 2021 and then plummeted by 95.42% in 2022.
  • Supernus Pharmaceuticals' Debt to Equity (Yearly) stood at $0.04 in 2020, then spiked by 1,153.04% to $0.52 in 2021, then crashed by 95.42% to $0.02 in 2022, then skyrocketed by 137.10% to $0.06 in 2023, then fell by 19.11% to $0.05 in 2024.